Association of copayment with likelihood and level of adherence in new users of statins: A retrospective cohort study

Journal of Managed Care Pharmacy

Volumn 20, Issue 1, 2014, Pages 43-50

  Watanabe, Jonathan H ^a   Kazerooni, Rashid ^b   Bounthavong, Mark ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANGINA PECTORIS; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DYSLIPIDEMIA; EMPHYSEMA; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; VASCULAR DISEASE;

AGED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES;

EID: 84890865334     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.1.43     Document Type: Article

References (28)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110(2):227-39.
2. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev Online. 2013;1:CD004816.
3. Fang WT, Li HJ, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2012;74(5):744-56.
4. Wang Z, Zhang Y, Gao M, et al. Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Pharmacotherapy. 2011;31(11):1051-62.
5. Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol. 2013;28(1):7-18.
6. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638-45.
7. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a populationbased retrospective cohort study in Israel. Clin Ther. 2008;30(11):2167-79.
8. Shalev V, Goldshtein I, Porath A, Weitzman D, Shemer J, Chodick G. Continuation of statin therapy and primary prevention of nonfatal cardiovascular events. Am J Cardiol. 2012;110(12):1779-86.
9. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12 Spec no.:SP11-19.
10. Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013;126(4):357.
11. Wu J, Seiber E, Lacombe VA, Nahata MC, Balkrishnan R. Medical utilization and costs associated with statin adherence in medicaid enrollees with type 2 diabetes. Ann Pharmacother. 2011;45(3):342-49.
12. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
13. Sinnott SJ, Buckley C, O'Riordan D, Bradley C, Whelton H. The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations: a systematic review and meta-analysis. PLoS One. 2013;8(5):e64914.
14. Choudhry NK, Fischer MA, Avorn JL, et al. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012;60(18):1817-24.
15. Kazerooni R, Watanabe JH, Bounthavong M. Association between statin adherence and cholesterol level reduction from baseline in a veteran population. Pharmacotherapy. 2013;33(10):1044-52.
16. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
17. Halpern MT, Khan Z M, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039-48.
18. Oleen-Burkey MA, Dor A, Castelli-Haley J, Lage MJ. The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate. J Med Econ. 2011;14(6):739-47.
19. Cheetham TC, Niu F, Green K, et al. Primary nonadherence to statin medications in a managed care organization. J Manag Care Pharm. 2013;19(5):367-73. Available at: http://amcp.org/WorkArea/DownloadAsset. aspx?id=16606.
20. Hanchate AD, Schwamm LH, Huang W, Hylek EM. Comparison of ischemic stroke outcomes and patient and hospital characteristics by race/ethnicity and socioeconomic status. Stroke. 2013;44(2):469-76.
21. Colvin JD, Z aniletti I, Fieldston ES, et al. Socioeconomic status and inhospital pediatric mortality. Pediatrics. 2013;131(1):e182-90.
22. Chu DI, Moreira DM, Gerber L, et al. Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2012;118(20):4999-5007.
23. Olson NA, Davidow AL, Winston CA, Chen MP, Gazmararian JA, Katz DJ. A national study of socioeconomic status and tuberculosis rates by country of birth, United States, 1996-2005. BMC Public Health. 2012;12:365.
24. Joynt M, Train MK, Robbins BW, Halterman JS, Caiola E, Fortuna RJ. The impact of neighborhood socioeconomic status and race on the prescribing of opioids in emergency departments throughout the United States. J Gen Intern Med. 2013 Jun 25. [Epub ahead of print].
25. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555-67.
26. Billups SJ, Malone DC, Carter BL. The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy. 2000;20(8):941-49.
27. Grabowski DC, Lakdawalla DN, Goldman DP, et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff(Millwood). 2012;31(10):2276-85.
28. Cutler DM, Everett W. Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553-55.